PUBLICATION:
Soliman et al. BMC Cancer (2020) 20:81

AUTHORS:
Hatem Soliman, Varsha Shah, Gordan Srkalovic, Reshma Mahtani, Ellis Levine, Blanche Mavromatis, Jayanthi Srinivasiah, Mohamad Kassar, Robert Gabordi, Rubina Qamar, Sarah Untch, Heather M. Kling, Tina Treece1, William Audeh

SUMMARY:
Results from the IMPACt trial measured changes in both treatment decisions and physician confidence when using the MammaPrint® and BluePrint® assays to support medical management for patients with early stage breast cancer.

Read more: Results from the IMPACt Trial Show Agendia Assays Consistently Inform Treatment Planning and Increase Physician Confidence when Caring for Patients with Early Stage Breast Cancer